AI has never had more attention. But the real transformation begins when it moves from promise to practice.

In this episode of Early Signs, Prashant Warier, Co-founder & CEO of Qure.ai, sits down with Dr. Amit Kakar, Managing Partner, Head of Novo Holdings Asia, for a wide-ranging conversation on what it will take for AI to create meaningful impact in healthcare.

Despite the extraordinary attention around AI, Amit believes its adoption across healthcare is still only at the “tip of the iceberg.” The opportunity now is to move beyond the hype and embed AI into the systems, workflows and decisions where it can make a real difference.

From radiologists working alongside AI to technology becoming almost invisible in clinical workflows, they explore what adoption could actually look like. They also get into how investors are thinking about AI companies, why Amit wouldn’t invest in a “pure AI” company, and where AI can create real value.

The conversation looks further ahead too to digital twins that could put a person’s entire health history at their fingertips, faster drug discovery and clinical trials, and just how far AI could ultimately take human health.

In this episode:

• Why AI adoption still lags behind the hype
• What happens to radiologists in an AI-enabled world
• Why the best healthcare AI could become almost invisible
• Why Amit wouldn’t invest in a “pure AI” company
• What healthcare investors are looking for in the AI era
• How digital twins could transform patient care
• How AI could accelerate drug discovery and clinical trials
• What healthcare could look like by 2050

Guest:

Dr. Amit Kakar

Managing Partner, Head of Novo Holdings Asia

Host:

Prashant Warier

Co-Founder & CEO, Qure.ai

AI is rapidly changing how we work, live, and make decisions. But what happens when that transformation reaches healthcare and ultimately, the patient?

In this episode of The Early Signs Podcast, our Co-Founder and CEO Prashant Warier sits down with Dr. Sunil Verma, SVP & Global Head of Oncology at AstraZeneca, for a wide-ranging conversation on what AI could mean for the future of healthcare and humanity.

From giving patients a stronger voice in their own care to transforming clinical decision-making, drug discovery, and healthcare delivery, Dr. Verma explores both the possibilities and the challenges that lie ahead.

He believes the next three years could define the incredible opportunity AI has to unleash.

Together, they explore:

* How AI could give patients a stronger voice in their own care

* Why treatment decisions may become increasingly complex as options multiply

* The promise and limitations of AI in drug discovery and clinical trials

* What it could take to move from "sick care" to more proactive, continuous care

* How organisations can build AI literacy and adoption

* The ethical guardrails needed as AI becomes more powerful

If you work in healthcare, life sciences, technology, or are simply curious about where AI is headed—this conversation offers a look at what comes next.

Guest:

Dr. Sunil Verma

SVP & Global Head, Oncology Franchise, AstraZeneca

Host:

Prashant Warier

Co-Founder & CEO, Qure.ai